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Chromatin immunoprecipitation coupled with DNA sequencing (ChIP-seq) is the major contemporary
method for mapping in vivo protein-DNA interactions in the genome. It identifies sites of transcription
factor, cofactor andRNApolymerase occupancy, as well as the distribution of histonemarks. Consortia such
as the ENCyclopedia Of DNA Elements (ENCODE) have produced large datasets using manual protocols.
However, futuremeasurements of hundreds of additional factors inmany cell types and physiological states
call for higher throughput and consistency afforded by automation. Such automation advances, when
provided by multiuser facilities, could also improve the quality and efficiency of individual small-scale
projects. The immunoprecipitation process has become rate-limiting, and is a source of substantial
variability when performedmanually. Herewe report a fully automated robotic ChIP (R-ChIP) pipeline that
allows up to 96 reactions. A second bottleneck is the dearth of renewable ChIP-validated immune reagents,
which do not yet exist for most mammalian transcription factors. We used R-ChIP to screen new mouse
monoclonal antibodies raised against p300, a histone acetylase, well-known as a marker of active enhancers,
for which ChIP-competent monoclonal reagents have been lacking. We identified, validated for ChIP-seq,
and made publicly available a monoclonal reagent called ENCITp300-1.
C
ontemporary studies of gene regulation are often based, at least in part, on learning the patterns of
chromatin mark distribution and the locations of specific transcription factor occupancy in the genome.
The chromatin immunoprecipitation (ChIP) assay, in several variations, provides this information1–3.
ChIP protocols typically begin by cross-linking proteins to DNA (usually with formaldehyde); then selectively
retrieving DNA fragments associated with a protein of interest by immunoprecipitation; and finally analyzing the
enriched DNA. Originally, ChIP-enrichment was analyzed using qPCR at predefined genomic regions4. Later, it
was coupled with microarray readouts (ChIP-chip/ChIP-on-chip) which allowed many selected regions to be
assayed in parallel (e.g. all promoters) or even whole genomes, especially in organisms with small genomes5–9.
Eventually, high-throughput sequencing enabled truly genome-widemapping of protein-DNA interactions, with
high resolution, in the form of ChIP-seq10–14.
ChIP-seq has become the workhorse for mapping the whole-genome occupancy and genomic distribution of
hundreds of transcription factors and numerous histone modifications in a wide variety of human, mouse, and
worm cell lines and tissues by the ENCODE15–18, mouse ENCODE19 and modENCODE consortia20,21, and the
NIH Roadmap Epigenomics Mapping Consortium22. Despite the large number of datasets generated thus far,
they are a small fraction of the expected future experiments from individual laboratories as well as consortia.
Initially, DNA sequencing capacity and cost were major barriers to large scale ChIP-seq, but sequencing capacity
has increased by several orders of magnitude and costs per ChIP have dropped significantly. The immunopre-
cipitation step has now emerged as rate-limiting. It is tedious, and in practice it is often variable from one
practitioner to another, from experiment to experiment, and even among replicates in a single experiment.
This suggested that a robust robotic ChIP protocol could stabilize and improve data quality, reproducibility,
manpower use, and overall costs and efficiency per experiment. An automated system would offer these benefits
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to individual laboratories doing small numbers of experiments,
through core facilities, in addition to enabling large-scale projects
and consortia.
A second independent challenge for contemporary ChIP-seq
experiments is that the supply of high-quality sustainable immune
reagents that have been experimentally validated for ChIP remains
very limited. Many antibodies, including some marketed as ‘‘ChIP-
grade’’ have failed in the ENCODE pipeline, and many that have
succeeded are polyclonal, which means that different lots can vary
radically in howwell they perform in ChIP23. At present, monoclonal
antibodies are the most reliable renewable ChIP reagents, although
they do not account for the majority of characterized reagents, and
there are noChIP-competent reagents for themajority of human and
mouse transcription factors. The field therefore faces the twin chal-
lenges of generating large quantities of ChIP-seq data in reliable
high-throughput manner for factors with extant affinity reagents,
and having to screen and characterize new sustainable immune
reagents.
In this work we develop a fully automated robotic pipeline for the
chromatin immunoprecipitation reaction (R-ChIP). High-through-
put 96-well plate methods for performing ChIP have been described
before24,25. However, those methods require substantial hands-on
time and are subject to variability inherent in experiments done by
humans. A conceptually similar robotic approach was recently
developed independently26, though it differs from the one presented
here in requiring manual intervention at several steps. The R-ChIP
protocol reported here is fully automated and employs a widely used,
multipurpose programmable liquid handling robotic platform
(Tecan Freedom EVO 200), which can be used for a multitude of
other purposes, such as robotic plasmid cloning or automated ELISA
screenings when it is not being used for ChIP. We test our protocol
on factors that have previously been characterized in multiple
ENCODE cell lines and show that it performs comparably to high
quality manual ChIP-seq in enrichment and in producing ChIP-seq
libraries that are consistent within and between experiments. We
then applied R-ChIP to screen candidate monoclonal antibodies
directed against the transcriptional co-activator p300, a protein for
which monoclonal ChIP-competent reagents have until now not
been available, and for which polyclonal reagent lots have been
highly variable.
Results
Automated ChIP protocol adaptations. The primary goal of this
work was to fully automate ChIP without compromising yield and
quality. Our design approachwas to develop automation thatmimics
as closely as possible the established manual process, using the
ENCODE ChIP protocol as the starting point (the current manual
ENCODE ChIP protocol is provided in the supplementary Appen-
dix). Where substantial changes were made to accommodate auto-
mation, the we benchmarked the new process against results from
the established protocol.
We configured a Tecan Freedom EVO 200 robot as detailed
(Figure 1 and Supplementary Figure 2), and programmed it for run-
ning automated chromatin immunoprecipitation reactions in a 96-
well format (the program itself is supplied as a supplementary file).
Major considerations for automating ChIP revolved around mag-
netic bead-handling to achieve successful incubation, washing, and
recovery of immunoprecipitated material, while effectively eliminat-
ing unbound chromatin. In the manual version of ChIP, bead agita-
tion is achieved by tumbling the reaction mix in standard Eppendorf
1.5-mL micro tubes on a tumbler wheel. The agitation device avail-
able on the robot is an orbital shaker with a 2-mm shake radius and
adjustable speeds ranging from 100 rpm to 1600 rpm. An alternate
method for automated bead agitation mixes by repeated pipetting
(trituration). We reasoned that pipetting would lead to inevitable
bead losses to the pipette surface, especially as multiple tip changes
would be required. We therefore focused on the orbital shaker. The
second automation constraint comes from the 96-well plate format
compared with individual microtubes in the manual protocol. This
change requires effective robotic washing without cross-contamina-
tion between wells or sample spillage.
Finally, the 96-well format requires a plate magnet strong enough
to efficiently pull down all beads. Several vendors offer plate magnets
compatible with the robot platform, but most are designed for stand-
ard low profile micro plates. In contrast, our automated ChIP pro-
tocol requires deep-well plates for effective bead washing. A magnet
designed specifically for deep-well plates (SPRIPlate Super Magnet
Plate fromAgencourt, BeckmanCoulter) proved effective. Its success
in our hands was optimal with a round-well-deep well plate with U-
bottom wells (catalog # 278752, Nunc). A summary of major differ-
ences for the robotic protocol is below and both protocols are given in
detail in the Supplementary Methods:
1. Bead agitation was changed from a tumbling motion in the
manual protocol to rapid orbital shaking. The shake speed
was optimized to keep beads fully suspended without spillage
(1400 rpm).
2. The sample volume was reduced from 1000 mL to 500 mL to
prevent spillage.
3. Wash steps after antibody and chromatin binding were
increased in number from 3 to 4 to compensate for the smaller
wash volume.
4. Bead recovery time on the magnet was extended to 7 min on
the robot, a condition determined empirically using the cri-
terion that no detectable beads were left behind in the super-
natant upon microscopic inspection.
5. The step that dissociates bound chromatin from antibody-mag-
netic beads is done in the robot’s PCRmodule, thus eliminating
constant bead agitation in themanual protocol during the 65uC
1 hour incubation. The beads are now suspended by the orbital
shaker after the 1 hour incubation.
Consistency of robotic ChIP results.We first tested the robustness
and reproducibility of our robotic ChIP protocol by carrying out
multiple manual and R-ChIP experiments for the NRSF/REST
transcription factor. NRSF/REST27,28 is a negative transcriptional
regulator of neuronal genes in non-neuronal cell types. It was the
first transcription factor to which ChIP-seq was applied11, its binding
has been extensively mapped in multiple cell lines, and its recogni-
tion site (and its binding variants) is well studied. The monoclonal
antibody used for NRSF ChIP has been well characterized in the
ChIP-seq format. It is thus a good system to characterize themethod.
We performed ChIP-seq experiments in two cell lines, GM12878
and Jurkat, producing at least three libraries from four separate plates
for GM12878 and from four separate plates for Jurkat.We compared
the resulting data to existing manually generated NRSF ChIP-seq
datasets for GM18278 cells16 and to four additional manual ChIP-
seq datasets generated in parallel with the R-ChIP ones. These data
are summarized in Figure 2.
To assess ChIP quality, we used library and ChIP QC metrics that
were developed previously by us and others as part of the ENCODE
Consortium29,30. The first question regarding ChIP quality is how
well the immunoprecipitation step has enriched for DNA fragments
attached to the antigen of interest. This can be assessed by calculating
the fraction of reads falling within called peaks (FRiP29) or by using
cross-correlation29,31. Bothmeasures have limitations in some special
cases30, but when both are applied and concur, confidence in the
results is high. Figure 2A shows the number of called peaks and
Figures 2B and 2C show the RSC (Relative Strand Correlation29)
and FRiP values for manual and robotic NRSF ChIP-seq datasets.
R-ChIP data consistently exhibited good RSC values (RSC$ 1) and
FRiP and peak number values comparable to those of manually
www.nature.com/scientificreports
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generated libraries, with the exception of three Jurkat libraries (the
first ChIP on plates 2, 3, and 4, Figure 2A, 2B and 2C) that scored as
less successful. We do not presently know the cause of these lower-
quality libraries, but their frequency is well within the range of vari-
ability of manually generated libraries we have observed over several
years, during which sporadic unsuccessful experiments for factor/
antibody pairs that are otherwise routinely successful have occurred.
Finally, we asked how similar the final sets of called peaks are for the
robotic protocol and how they compare with reference manual data-
sets for the same factor and cell type, by evaluating peaks called after
sequencing. Figures 2D and 2E show the similarity of peak call sets
for all libraries measured by calculating the size of the overlap
between each pair of libraries. Overall, we observed consistently high
overlap scores and thus high reproducibility between libraries. These
observations applied both within and between plates, underscoring
the consistency and robustness of the R-ChIP protocol.
Figure 1 | Illustration of individual automated ChIP protocol steps. A Tecan Freedom EVO 200 robot equipped with a Liquid Handling arm (LiHa), a
Multi Channel Arm (MCA) and Robotic Manipulator arm (RoMa) is used for all steps. Additional devices integrated into the robot are standard-
size plate carriers, magnet plate, orbital plate shaker and PCRmachine. The cartoons in the left column illustrate each protocol step, described in the flow
diagram in the second column. The cartoon sequences on the right illustrate the robotic process step sequences used for each protocol step. The white
arrows pointing to the protocol steps indicate which robot sequences apply to each protocol step.
www.nature.com/scientificreports
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Figure 2 | Reproducibility of R-ChIP experiments. Multiple ChIP-seq experiments on multiple plates were generated for the NRSF/REST repressor in
GM12878 lymphoblastoid cells (n5 4 plates) and Jurkat T-cells (n5 4 plates) cell lines. The numbers (1 through 5) refer to the number of the plate a
library came from, ‘‘M’’ refers tomanually generated datasets. The first twomanual GM12878 datasets were previously published as part of the ENCODE
project, the next four were generated in parallel with the R-ChIP ones. (A) Number of called regions for each dataset (using ERANGE 4.011) (B)
Assessment of ChIP enrichment using RSC (Relative Strand Correlation) cross-correlation scores29; (C) Assessment of ChIP enrichment using FRiP
(Fraction of Reads in Peaks) scores (Landt et al. 2012); (D) Overlap between called peaks in robotic and manual ChIP libraries in GM12878 cells; (E)
Overlap between called peaks in robotic and manual ChIP libraries in Jurkat cells. The overlap score (OXY) shown in each box indicates the fraction of
peaks in the dataset on the y-axis that are also found in the dataset on the x-axis, i.e. OXY 5 |X > Y | / |Y | .
www.nature.com/scientificreports
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To further characterize the consistency between the results from
R-ChIP and manual ChIP experiments, we generated paired manual
and robotic ChIP-seq datasets using matched chromatin samples for
several additional targets (Figure 3). These included the H3K27ac
histone modification (Figure 3A, 3B and 3C), the GABP transcrip-
tion factor32–34 (Figure 3D, 3E and 3F), the ZBTB33/Kaiso zing-finger
protein known for its preferential binding to methylated DNA35
(Figure 3G, 3H and 3I), and the important regulator of hematopoi-
esis SPI1/PU.136,37 (Figure 3J, 3K and 3L). We observed comparable
results between the manual and robotic datasets, further confirming
the applicability of R-ChIP to large-scale ChIP-seq production.
Using R-ChIP to characterize new monoclonal p300 antibodies.
Having established the R-ChIP protocol, we next applied it to
Figure 3 | Comparison between manual ChIP and R-ChIP results for additional targets. Manual and robotic ChIP-seq datasets were generated in
parallel using the same chromatin samples and the result compared. (A,B,C) ChIP-seq against H3K27ac in GM12878 cells. (A) FRiP score, (B) number of
peaks called, (C) overlap between the sets of peaks; (D,E,F) ChIP-seq against GABP in GM12878 cells. (D) FRiP score, (E) number of peaks called, (F)
overlap between the sets of peaks; (G,H,I) ChIP-seq against ZBTB33 in GM12878 cells. (G) FRiP score, (H) number of peaks called, (I) overlap between
the sets of peaks; (J), (K), (L) ChIP-seq against PU.1 in GM12878 cells. (J) FRiP score, (K) number of peaks called, (L) overlap between the sets of peaks.
The overlap score (OXY) shown in each box indicates the fraction of peaks in the dataset on the y-axis that are also found in the dataset on the x-axis, i.e.
OXY 5 |X > Y | / |Y | .
www.nature.com/scientificreports
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characterize a set of monoclonal antibodies raised against the p300
transcriptional co-activator in the Beckman Institute Protein
Expression Center and Monoclonal Antibody Facility at Caltech.
The p300 protein is a histone acetyltransferase, best known for its
role in the acetylation of histones38–41. It is used as a marker of active
transcriptional enhancers in mammalian genomes42–45. Commer-
cially available antibodies used to generate published p300 data are
from a series of polyclonal nonrenewable reagents that have a
reputation for lot-to-lot variability.
We generated 11 a-p300 mouse monoclonal antibodies which
were initially screened, cloned and then rescreened using a plate-
based ELISA assay. We tested hundreds of individual hybridoma
B-cells isolated after fusion with cells from spleens of mice injected
with a GST-tagged p300 protein fragment (aa 152–213) or a syn-
thetic KLH-coupled peptide (aa 1526–1545). The GST-tagged pre-
parations were subjected to formaldehyde fixation (1% FA for
10 min) before immunization with the goal of increasing the like-
lihood of reactivity in ChIP. The resulting 11 p300 monoclonal anti-
bodies were tested for ChIP together with two lots of rabbit
polyclonal p300 antibodies (Santa Cruz sc-585, lot numbers F2711
and E3113) on chromatin from GM12878 cells. The resulting data-
sets were compared to each other and to publicly available ENCODE
p300 data from the same cells (using two commercially available
rabbit polyclonal antibodies, Santa Cruz sc-585 and sc-584)
(Figure 4). Three of the mouse monoclonal antibodies raised against
the synthetic KLH-coupled p300 peptide scored positive by ChIP-
seq, identifying between 1,524 and 4,870 peaks (Figure 4A and 4B).
We sequencedmultiple additional replicates for the best-scoring one,
1F4-E10P and identified an even higher number of peaks in some of
the datasets, up to 8,430, with the typical number being,6,000. The
peaks called in the monoclonal antibody dataset are a subset of those
found in the polyclonal data (Figure 4C) confirming the specificity of
the antibodies towards p300. While the monoclonal numbers are
lower than the two most successful polyclonal datasets, they are
within the range of what was previously observed in ENCODE data,
and also within the range of published p300 datasets. We have
renamed p300 1F4-E10P as ENCITp300-1 and submitted it under
this name to the Developmental Studies Hybridoma Bank (http://
dshb.biology.uiowa.edu/).
It was not our purpose in this study to characterize new polyclonal
reagent lots, but the p300 reagents used previously by ENCODEwere
no longer available. We therefore used two additional rabbit poly-
clonal antibodies in R-ChIP (Santa Cruz sc-585, lot numbers E3113
and F2711), and they identified up to ,30,000 peaks. This number
greatly exceeds previously published p300 datasets, including cur-
rently available ENCODE data for the sameGM12878 B-cell line (for
which between 2,610 and 12,924 peaks were called previously)
(Figure 4A and 4B). This increase has two likely causes, and they
are not mutually exclusive. The first well-appreciated variable is
different performance by polyclonal antibody lots. In principle, indi-
vidual lots can vary in the number and identity of epitopes recog-
nized, in effective antibody concentration, and in non-specific
reactivity. A second difference from the prior ENCODE data is the
fixation condition. For p300, we fixed cells at 37uC for 30 minutes,
versus room temperature for 10 minutes for the historic ENCODE
data. This condition was suggested to us by Dr. Bing Ren, UC San
Diego, and is based on the idea that a longer time and elevated
temperature might increase p300 cross-linking via indirect links to
DNA-bound transcription factors or histones. This condition sig-
nificantly improves p300 ChIP in our hands (for example, we gen-
erated datasets using the 1F4-E10P antibody on chromatin fixed
under standard conditions and they were all unsuccessful;
Supplementary Figure 4). Of the 30,000 p300 peaks called using
the 37uC fixation condition, the majority (between 76% and 88%)
overlap with one or more chromatin marks associated with enhan-
cers and promoters in ENCODE data (H3K27ac; H3K4me1) or with
regions of DNAse hypersensitivity (Supplementary Figure 3). This is
consistent with these regions being active enhancers and promoters.
For multiple cell types, the numbers of DNAse hypersensitive
regions46,47, H3K27ac and H3K4me1 positive regions, reported prev-
iously are typically in the tens of thousands (ENCODE Project
Consortium 2012), and the number of expressed genes per cell type
is between 5 and 103 103. Thus the expected number of enhancers
(and potentially p300-positive regions) is larger than the single-digit
thousands of p300 peaks called in most previously available data.
While reagent-specific background, including possible polyclonal
cross-reactivity, could explain themodest number of p300 peaks that
lack additional enhancer or promoter marks, the most parsimonious
explanation for the overall very large number of newly revealed p300
peaks is that prior ChIP measurements have underestimated p300
occupancy. The monoclonal peaks also correspond preferentially to
the strongest sites called for the polyclonals under the 37uC fixation
condition (Supplementary Figure 8). Our best-performing monoclo-
nal antibody did not produce comparably high peak numbers using
the same chromatin substrate, but 99% of its peaks overlap those
called in the polyclonal datasets. We note that the polyclonal anti-
body lots used here are also no longer in stock from the
manufacturer.
We then tested additional factors with the 37uC fixation condition.
Results were very similar to those with the standard condition for
NRSF, H3K27ac and GABP (Supplementary Figure 5, Supplemen-
tary Figure 6A–F), suggesting that the more aggressive fixation con-
dition does not result in general nonspecific background. However,
for PU.1 and ZBTB33, the 37uC fixation led to fewer peaks and
overall lower quality ChIP data (Supplementary Figure 6G–L). As
discussed below, our data suggest that the impact of fixation con-
dition on ChIP outcome might be more complex than is generally
acknowledged, and that a wider survey of factor-antibody pairs rela-
tive to fixation conditions will be needed.
Discussion
The robotic ChIP (R-ChIP) reported here was developed on a widely
used commercial liquid-handling platform whose configuration and
running program for ChIP are provided. It was developed to increase
ChIP-seq throughput, uniformity, and quality, while reducing
investigator tedium and error. It should be equally applicable for
large-scale projects or for smaller, individual-lab projects carried
out in multiuser core facilities.
Our R-ChIP results were comparable in quality to those from a
large-scale manual pipeline by multiple metrics. However the plat-
form’s performance is not perfect. We expect that we and others will
continue to make improvements. Specifically, we have observed
sporadic single reaction failures among replicate samples within an
individual plate, possibly associated with edge and corner well posi-
tions (Supplementary Figure 7), but sporadic failures are also
observed with manual experiments. It is our standard practice to
include on each R-ChIP plate a minimum of triplicate control sam-
ples deployed across the plate geometry. For these controls, we use a
monoclonal reagent and a large batch of control chromatin that
permits comparisons between plates through time. This allows us
to evaluate each plate run and to compare it with other runs. This
evaluation can be done as a QC step before committing to building
and sequencing all remaining libraries. This gating step has clear
economic implications.
ChIP troubleshooting is aided by R-ChIP. If a group of failed
samples are embedded in a large R-ChIP run where the controls
and other samples are successful, it becomes unlikely that the ChIP
process is the source of failure, and a user can turn attention to the
input sample and immune reagent (or any post-ChIP variation) as a
more likely problem. Of course, the overall success of a ChIP-seq
measurement includes the local DNA sequencing process,with spe-
www.nature.com/scientificreports
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cific sequencing protocols being differentially sensitive to the mass,
fragment size, and other characteristics of a ChIP sample.
We used R-ChIP to screen for monoclonal ChIP-competent anti-
bodies for the histone acetyltransferase, p300.Many antibodiesmade
against transcription factors fail in ChIP reactions, even though they
work well in one or more conventional uses (e.g. standard immuno-
precipitation, western blots or immunocytochemical stains).
Moreover, polyclonal reagents that are ChIP-seq compatible typ-
ically vary, sometimes greatly, in their specificity and performance
from lot to lot23. The upshot has been that the only way to identify a
ChIP-quality antibody is to test it directly for ChIP, and the most
general way to ensure reliability and unlimited supply is with a
monoclonal. Whether the final readout for ChIP competence is
DNA sequencing or qPCR (the latter requiring known targets for
the factor), the capacity to test many ChIP reactions is critical for
screening. The ChIP peaks identified by our top monoclonal,
ENCITp300-1 (originally called 1F4-E10P during screening) overlap
highlywith priormeasurements fromENCODE for the same cell line
and with concurrent polyclonal determinations, confirming its spe-
cificity for p300 and the utility of R-ChIP for screening new immune
reagents for ChIP. This reagent is beingmade publicly available at the
Developmental StudiesHybridomaBank.We note, however, that the
data obtainedwith it are not as inclusive as the best datasets produced
using polyclonal rabbit reagents.
Figure 4 | Characterization of novelmonoclonal p300 antibodies using robotic ChIP.ChIP-seq against p300 was carried out in GM12878 cells and prior
ENCODE data for it in that cell line (from the ‘‘SYDH’’ production group) was used as a reference. ENCODE data was generated using two
different rabbit polyclonal antibodies from Santa Cruz (sc-584 and sc-585). We carried out robotic ChIP testing of two different lots of the sc-585
antibody and 11 different monoclonals we raised. The 1F4-E10P clone scored best and additional replicates were generated in subsequent experiments.
(A) Number of called regions; (B) ChIP enrichment as measured by FRiP scores (Landt et al. 2012); (C) Overlap between called peaks with different
antibodies. The overlap score (OXY) shown in each box indicates the fraction of peaks in the dataset on the y-axis that are also found in the dataset on the x-
axis, i.e.OXY5 |X> Y | / |Y | ; (D) Representative browser snapshot of p300 ChIP enrichment in polyclonal andmonoclonal datasets around the IL13 and
IL4 locus.
www.nature.com/scientificreports
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For p300 R-ChIP, we used chromatin from cells fixed with a
modified condition (37uC, 1% formaldehyde, 30 min; personal com-
munication, Bing Ren, UC San Diego). This improved p300 ChIP
significantly in our hands compared with our standard fixation con-
dition (see Results andMethods), while it had no detectable effect on
NRSF, GABP and H3K27ac ChIP. We also observed that the PU.1
and ZBTB33 ChIP-seq datasets we generated were not as good with
37uC chromatin as with the standard condition. Until more factors
are tested directly under both fixation conditions, we cannot predict
which antibody-factor pairs will be affected or how. Epitope destruc-
tion or occlusion, or elevated signals from lower affinity interactions,
are among the plausible negative effects. The most positive impact is
expected for proteins that interact indirectly with DNA, as p300 is
understood to do.
We anticipate that R-ChIP, and variations on it, will advance a
wide range of functional genomics studies by relieving the emerging
data production bottleneck, increasing efficiency and improving
overall data quality.
Methods
Cell growth and harvesting. Cells were grown and harvested following established
ENCODE protocols (available at http://genome.ucsc.edu/ENCODE/cellTypes.html)
with the exception of GM12878 p300 experiments for which chromatin was fixed at
37uC for 30 minutes.
Chromatin preparation. Chromatin was cross-linked by adding formaldehyde
directly to the cell culturemedia at a final concentration of 1% and gentlymixed for 10
minutes. The exception was (where indicated) fixation at 37uC for 30 minutes, which
was used for p300 experiments. In all cases, the formaldehyde reaction was quenched
by adding glycine to a final concentration of 0.125 M for 10 minutes. Cells were then
pelleted, rinsed once in cold phosphate-buffered saline (PBS) with 1 mM PMSF and
once in cold MC lysis buffer (10 mM Tris pH 7.5, 10 mMNaCl, 3 mMMgCl2, 0.5%
NP-40, and Roche Complete Protease Inhibitor Cocktail) to obtain nuclear pellets.
Nuclei were sonicated in RIPA buffer (PBS, 1% NP-40 Substitute, 0.5% Sodium
Deoxycholate, 0.1% SDS, and Roche Complete Protease Inhibitor Cocktail) at a
concentration of at least 53 107 nuclei/mL using a probe sonic dismembrator from
Fisher Scientific (Model 550). To check for fragment size distribution after sonication,
a small fraction of the sample was reverse cross-linked for two hours at 65uC, purified
usingDNApurification columns fromQiagen, then loaded onto a 2% agarose EtBr E-
Gel from Invitrogen (Supplementary Figure 9).
Antibodies used.The following antibodies were used: an a-NRSFmousemonoclonal
(12C11) from the Anderson Lab at Caltech11,48, an a-p300 rabbit polyclonal (sc-585)
from Santa Cruz Biotechnology, amousemonoclonal a-GABP (sc-28312) from Santa
Cruz Biotechnology, a mouse monoclonal a-Kaiso/ZBTB33 (sc-23871) from Santa
Cruz Biotechnology, a rabbit polyclonal a-SPI1/PU.1 (sc-22805) from Santa Cruz
Biotechnology, and a mouse monoclonal a-H3K27ac (306–34849) from Wako. In
addition 11 a-p300 mouse monoclonals were generated in the Caltech Mouse
Monoclonal Facility. Four of the a-p300 mouse monoclonals were raised against a
bacterially expressed GST fusion protein containing N-terminal residues 152–213.
The remaining seven antibodies were raised against a synthetic peptide from
GenScript containing residues 1526–1545.
Robotic-ChIP (R-ChIP) workflow. ChIP experiments were adapted from
methods previously described and optimized for performance in a 96-well plate
format using a Tecan Freedom EVO 200 liquid handling robot. Reagents and labware
are placed on deck of the robot (Supplementary Figure 1).
After setup the R-ChIP workflow is completely hands-off and consists of a series of
modules with a run time of,24 hours, including the 12-hour reverse cross-linking step.
All aspects of the setup are checked thoroughly to ensure a smooth run.
1. Blocking and washing of magnetic beads. The Tecan begins by resuspending
magnetic beads (Invitrogen M-280 Dynabeads) from the source tube with the
liquid-handling arm (LiHa) and dispenses themagnetic beads into a Fisher 96-
Well DeepWellTM Polypropylene known as the ChIP plate. 100 mL of beads is
used for a monoclonal IP antibody and 200 mL for a polyclonal. The LiHa tips
are evacuated and rinsed with ddH2O between subsequent dispenses to pre-
vent cross-contamination. 500 mL of PBS containing 5% bovine serum albu-
min (BSA) is then dispensed by the LiHa from a buffer reservoir (Te-Fill) to
block and wash the magnetic beads. The plate containing the beads is trans-
ferred to an orbital mixer (Te-Shake) with the robotic manipulator arm
(RoMa) and mixed several times for 20 seconds with a 20 second pause
between each mix. The RoMa moves the bead plate to a magnetic plate for
seven minutes where the beads are then pelleted in a ring allowing the multi-
channel arm (MCA96) fitted with natural 200 mL tips from TipOne to aspirate
liquid. These steps are repeated three more times and include an ethanol rinse
of the MCA96 tips as needed to prevent cross-contamination.
2. Binding of antibody tomagnetic beads. The LiHa adds 400 mL of PBS-BSA to
the antibody plate bringing the final volume to 500 mL. The antibody is then
added to the beads using the MCA 96 which transfers the diluted antibody
from the a 2.0-mL 96-well PlateOne V-bottom plate to the ChIP plate. For
monoclonal antibodies, 5 mg of antibody were diluted in 500 mL (10 mg for
polyclonals). The beads and antibody are incubated together for one hour with
mixing using the Te-Shake. Any unbound antibody is then aspirated with the
MCA96 and deposited into a fresh 2.0-mL 96-well PlateOne V-bottom plate
for further analysis if needed.
3. Incubation of chromatin and antibody-bead complex. The MCA96 transfers
500 mL of chromatin containing 2.5 3 107 cells from the Matrix tube rack to
the ChIP plate. The chromatin and antibody bead complex are then incubated
together for 2 hours during which the ChIP plate alternates between the Te-
Shake and a 4uC cool plate using the RoMa. The chromatin is stored in 1.2 mL
screw-top Matrix tubes that can be arrayed on the chromatin plate as needed.
Any unbound chromatin is then aspirated with theMCA96 and deposited into
a fresh 2.0-mL 96-well PlateOne V-bottom plate for further analysis if needed.
4. Washing of IP complex. The LiHa dispenses 500 mL of LiCl wash buffer
(100 mM Tris pH 7.5, 500 mM Lithium Chloride, 1% NP-40, 1% sodium
deoxycholate) from the Te-Fill onto the beads, which are then mixed for 20
seconds with 20 second pauses between each mix. The beads are then pelleted
and the wash with LiCl buffer is repeated four more times. The LiHa then adds
500 mL of TE buffer (10 mM Tris pH 7.5 and 1 mM EDTA) and resuspends
the beads with the Te-Shake for 20 seconds. Beads are then pelleted with the
magnetic plate and any remaining buffer is aspirated and discarded by the
MCA96.
5. Elution from beads. The LiHa dispenses 100 mL of IP elution buffer (1% SDS
and 0.1 M NaHCO3) from the Te-Fill and the beads are resuspended by mix-
ing for 20 seconds with the Te-Shake. TheMCA96 then aspirates the beads and
transfers them from the ChIP plate to a Hard-Shell Semi-Skirted PCR Plate
from Bio-Rad. The RoMa transfers a PCR lid from the storage hotel and places
it on top of the PCR plate then transfers the lidded PCR plate to a DNA Engine
Peltier Thermal Cycler with Remote Alpha Dock System from Bio-Rad. The
top of the thermal cycler closes and places force on the PCR plate lid creating a
seal. The beads are then heated for one hour at 65uC to disassociate the IP
complex from the magnetic beads.
6. Reversal of Cross-links. The RoMa takes the PCR plate from the thermal cycler
and transfers it to the Te-Shake to resuspend the beads. The PCR plate is then
transferred to themagnetic plate for pelleting of the beads. TheMCA96mounts
50 mL Tecan Pure Disposable tips from Tecan, slowly aspirates the supernatant,
and transfers it to a fresh PCR plate. 10 mL of proteinase K from Epicentre
diluted 155 in proteinase K buffer (50% glycerol, 50 mM Tris-HCl pH 7.5,
0.1 M NaCl, 0.1 mM EDTA, 1 mMDTT, 10 mM CaCl2, 0.1% TritonH X-100)
is then added to the supernatants with the LiHa. The RoMa places a lid on the
fresh PCR plate and transfers both back to the thermal cycler for a 12 hour
incubation at 65uC to reverse the cross-links. Once the incubation is finished
the plate is transferred to the deck with the RoMa and the R-ChIP is complete.
DNA cleanup. Samples from the R-ChIP ChIP experiments presented here were then
cleaned up manually using the protocol described by Qiagen in their Qiaquick
PCR purification kit with the addition that the EB buffer is heated to 55uC prior to
elution and eluted in a 50 mL volume using DNA lo-bind 1.5 mL tubes from
Eppendorf. We anticipate automating this step.
Library building and sequencing. Library building for sequencing on the Illumina
HiSeq platformwas performed conventionally with barcoding to allowmultiple ChIP
libraries to be sequenced in a single flow cell lane, according to the HudsonAlpha
ENCODEChIP protocol (SupplementaryMethods). Standardmethods were used for
end repair and dA addition of DNA fragments recovered from ChIPs or chromatin
controls. The fragments were then ligated to Illumina Paired-End adaptor sequences
and PCR-amplified to complete the adaptor sequences and introduce a 7-base DNA
barcode in the i7 position. The barcodes allowed mixing of multiple samples per
flowcell lane. Control libraries were prepared from 500 ng of DNA from reverse
crosslinked sonicated chromatin. ChIP library starting amounts varied, with a
median of 7.5 ng. Fragment size selection was achieved at the lower threshold with
solid phase reversible immobilization (SPRI) technology to recover dsDNA greater
than 100 bp after adaptor ligation (thereby excluding unligated adaptors) and at the
upper threshold with an extension time of 30 seconds during PCR amplification. This
size selectionmethod consistently produced final DNA library fragments that ranged
from,100 to 400 bp, as determined by BioAnalysis. Final library amounts varied by
ChIP, with a median of 546 ng.
Detailed description of the protocol can be found in the Supplementary Methods.
Libraries were pooled in equimolar amounts and sequenced on the Illumina
HiSeq2000 or HiSeq2500 with 50 bp single-end reads following the manufacturer’s
recommendations. Raw sequencing reads are available from GEO accession number
GSE53366.
Data processing and analysis.Reads were aligned using Bowtie49, version 0.12.7, with
the following settings: ‘‘-v 2 -t -k 2 -m 1 --best --strata’’, which allow for two
mismatches relative to the reference and only retain unique alignments, against the
hg19 version of the human genome (assembly downloaded from the UCSC genome
www.nature.com/scientificreports
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browser) with the Y chromosome retained or removed depending on the sex of the
cell line. Peak calling was carried out using ERANGE11, version 4.0, with the following
settings: ‘‘--minimum 2 --ratio 3 --listPeak --shift learn --revbackground’’, against
matching control samples. Library complexity was estimated as described
previously29. Cross-correlation analysis was carried out using version 1.10.1 of SPP31)
and the following parameters: ‘‘-s 5 0525400’’.
All additional analysis was carried out using custom-written Python scripts.
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